WEDGEWOOD PHARMACY: A portfolio company of New Harbor Capital, has agreed to be sold to Partners Group
Highlights Lincoln International's leading advisory position in the animal health sector Read More »
Highlights Lincoln International's leading advisory position in the animal health sector Read More »
MHA Study Reveals Member Medication Adherence Rates for Long-Term Care Pharmacies Serving Skilled Nursing and Assisted Living Patients Read More »
Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. It is also the second U.S. FDA NDA submission in the central nervous system (CNS) filed by the company. Read More »
MedicaSafe will combine the generic version of Suboxone® (buprenorphine and naloxone) with its smart medication systems to treat opioid dependence Read More »
Acquisition is expected to realize over $10M in annual synergies Read More »
PharmScript, a leading pharmacy provider to long-term care and post-acute care facilities, announced the opening of a new pharmacy in Abilene, Texas. Read More »
Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes Read More »
This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients Read More »
The U.S. Food and Drug Administration (FDA) has approved Cablivi®(caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Read More »
Aquestive Therapeutics, Inc. (Nasdaq: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, announced that the U.S. District Court for the District of New Jersey has granted a temporary restraining order (TRO) that enjoins Alvogen from initiating any launch activities related to its generic buprenorphine/naloxone sublingual film. Read More »
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). Read More »
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in regards to its New Drug Application (NDA) for tadalafil oral film (OF). Read More »
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Read More »
Allergan issued the following announcement on Sept. 26.Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Read More »
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10 Read More »
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved GRANIX® (tbo-filgrastim) Injection for a new vial presentation and indication in pediatric patients 1 month and older. Read More »
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has granted Fast Track designation for AGN-241751, an investigational new treatment for Major Depressive Disorder (MDD). AGN-241751 is a novel, oral, rapid-acting anti-depressant that recently entered Phase 2 development. Read More »
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC). Read More »
Sandoz Inc. (Sandoz), a Novartis Division, today announced an exclusive agreement with Adamis Pharmaceuticals Corporation (Adamis) whereby Sandoz will distribute and commercialize SYMJEPI™ (epinephrine) 0.3 mg Injection in the United States. Read More »
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S Food and Drug Administration (FDA) has accepted for standard review a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act (PDUFA), or target action, date of February 16, 2019. Read More »